Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 2/20 | 0.47 |
| ▸ | KIT | P10721 | 1/20 | 0.46 |
| ▸ | CKS1B | P61024 | 2/20 | 0.45 |
| ▸ | SKP1 | P63208 | 2/20 | 0.45 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.45 |
| ▸ | GBA1 | P04062 | 2/20 | 0.44 |
| ▸ | BACE1 | P56817 | 3/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.42 |
| ▸ | HTR6 | P50406 | 2/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.41 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.41 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3831589 | 0.81 | PIK3CA (0.51) | PIK3CACKS1BSKP1SKP2BACE1 | |
| SCHEMBL5761659 | 0.80 | PIK3CA (0.49) | PIK3CAACHEKITCKS1BSKP1 | |
| SCHEMBL5763597 | 0.80 | HTR6 (0.67) | PIK3CAACHEKITCKS1BSKP1 | |
| SCHEMBL2197307 | 0.79 | HTR2A (0.63) | PIK3CAACHEKITCKS1BSKP1 | |
| SCHEMBL5203242 | 0.79 | HTR6 (0.52) | PIK3CAACHECKS1BSKP1SKP2 | |
| SCHEMBL6581755 | 0.79 | HTR6 (0.64) | PIK3CACKS1BSKP1SKP2GBA1 | |
| SCHEMBL5202405 | 0.79 | HTR6 (0.70) | PIK3CAKITCKS1BSKP1SKP2 | |
| SCHEMBL5763068 | 0.79 | HTR6 (0.64) | HTR6 | |
| Hydrochloric Acid SCHEMBL5761759 | 0.78 | HTR6 (0.62) | HTR6 | |
| SCHEMBL2195197 | 0.76 | HTR2A (0.59) | PIK3CAACHEKITCKS1BSKP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1497291-B1 | QUINOLINE AND AZA-INDOLE DERIVATIVES AND THEIR USE AS 5-HT6 LIGANDS | GLAXO GROUP LTD (GB) | 2006-11-22 | — | — | EP | disclosed |
| US-20050124626-A1 | Novel compounds | GLAXO GROUP LIMITED (GB) | 2005-06-09 | — | — | US | disclosed |
| EP-1497291-A2 | QUINOLINE AND AZA-INDOLE DERIVATIVES AND THEIR USE AS 5-HT6 LIGANDS | GLAXO GROUP LIMITED (GB) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003080608-A2 | QUINOLINE AND AZA-INDOLE DERIVATIVES AND THEIR USE AS 5-HT6 LIGANDS | GLAXO GROUP LIMITED (GB) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124626-A1 | Novel compounds | AANAT, INMT, CHRNA5 | PIK3CA 1616/4885ACHE 55/4885KIT 2558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.